EP 0828712 A1 19980318 - BETA-ADRENERGIC AGONISTS
Title (en)
BETA-ADRENERGIC AGONISTS
Title (de)
BETA-ADRENERGISCHE AGONISTEN
Title (fr)
AGONISTES DU RECEPTEUR BETA-ADRENERGIQUE
Publication
Application
Priority
- CA 2220538 A 19950510
- IB 9500342 W 19950510
Abstract (en)
[origin: WO9635670A1] beta -adrenergic agonists for the treatment of diseases/conditions such as obesity and diabetes. The compounds have formula (I) wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, W, X, Y and Z are as defined in the specification.
[origin: WO9635670A1] beta -adrenergic agonists for the treatment of diseases/conditions such as obesity and diabetes. The compounds have formula (I) wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, W, X, Y and Z are as defined in the specification.
IPC 1-7
IPC 8 full level
A23K 1/16 (2006.01); A61K 31/44 (2006.01); A61P 1/14 (2006.01); A61P 3/00 (2006.01); A61P 3/06 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61P 11/00 (2006.01); A61P 13/02 (2006.01); A61P 15/00 (2006.01); A61P 25/24 (2006.01); A61P 25/26 (2006.01); C07D 213/73 (2006.01); C07D 213/74 (2006.01); C07D 487/04 (2006.01); C07F 7/10 (2006.01); C07D 239/42 (2006.01)
IPC 8 main group level
C07D (2006.01)
CPC (source: EP)
A61P 1/14 (2017.12); A61P 3/00 (2017.12); A61P 3/06 (2017.12); A61P 3/08 (2017.12); A61P 3/10 (2017.12); A61P 11/00 (2017.12); A61P 13/02 (2017.12); A61P 15/00 (2017.12); A61P 25/24 (2017.12); A61P 25/26 (2017.12); C07D 213/73 (2013.01); C07D 239/42 (2013.01)
Citation (search report)
See references of WO 9635670A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9635670 A1 19961114; CA 2220538 A1 19961114; CN 1144801 A 19970312; EP 0828712 A1 19980318; FI 974170 A0 19971107; FI 974170 A 19971107; JP H11504648 A 19990427
DOCDB simple family (application)
IB 9500342 W 19950510; CA 2220538 A 19950510; CN 96105900 A 19960507; EP 95915993 A 19950510; FI 974170 A 19971107; JP 53390296 A 19950510